Progenics announced that AZEDRA has been added to the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for Neuroendocrine and Adrenal Tumors v 3.2018. NCCN Guidelines are widely recognized and used as the standard for clinical policy in oncology by clinicians and payors.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.